⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399226 | 0.88 | — | — | |
| SCHEMBL16832104 | 0.88 | CA1 (0.32) | — | |
| SCHEMBL16831667 | 0.85 | CA1 (0.32) | — | |
| SCHEMBL23722514 | 0.75 | — | — | |
| SCHEMBL12831735 | 0.75 | — | — | |
| SCHEMBL2815562 | 0.72 | — | — | |
| SCHEMBL883061 | 0.69 | — | — | |
| SCHEMBL6876381 | 0.67 | — | — | |
| SCHEMBL4979226 | 0.67 | CA1 (0.30) | — | |
| SCHEMBL393019 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 992 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-109761944-A | A kind of chrysin amide derivatives and preparation method thereof and medical usage | 武汉翼博济生生物科技有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-109251588-A | Inorganic nano material ink and its preparation method and application, QLED device | TCL集团股份有限公司 | 2019-01-22 | — | — | CN | claimed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-1505945-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004032827-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-1996024591-A1 | CYCLOALKYLSULPHONYL-AMINOSULPHONYL UREAS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |